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1. Introduction 
The serum protein CQHS glycoprotein acts as an 
opsonin during bacterial phagocytosis by neutrophils 
[ 1 ] and enhances macrophage phagocytic function 
[2]. In addition CQHS glycoprotein binds to DNA [3] 
and promotes the endocytosis of radio-labelled DNA 
by mouse macrophages [4]. DNA-protein complexes 
are present on the surface membrane of Ehrlich ascites 
tumour cells [5]. We therefore wondered whether 
(rlHS glycoprotein could bind to lymphocytes trans- 
formed by Epstein-Barr virus (EBV) a DNA virus 
which is implicated as an oncogenic agent [6]. This 
could presuppose a role for cr?HS glycoprotein as a 
soluble mediator enhancing cell-mediated host defense 
mechanism against EBV-transformed cells. The binding 
of a,HS glycoprotein to EBV-transformed lymphocytes 
was studied by indirect immunofluorescence as well 
as directly by the use of 1251-labelled (w2HS glycopro- 
tein. We conclude 02HS glycoprotein binds appreciably 
to EBV-transformed but not to normal autologous 
non-transformed lymphocytes, Kd = 5 .O X IO-’ M 
with 0.5 X lo6 sites/cell. 
lymphocytes were cultured in Hepes-buffered RPM1 
supplemented with 15% fetal calf serum (FCS, Gibco 
Batch 182), 2 mM L-glutamine and maintained in 95% 
sir/5% COa at 37°C. 
For indirect immunofluorescence eosin-viable trans- 
formed cells (10’) were washed 3 X with Hepes-buff- 
ered RPM1 supplemented with 15% FCS (Gibco, Batch 
182), 2 mM L-glutamine, 0.02% NaNa (RPMI/FCS) 
and incubated 60 min at 22°C with an equal volume 
of purified a2HS glycoprotein solution (1.6 mg/ml in 
PBS). The cells were rewashed 3 X with RPMI/FCS 
and incubated, 60 min at 22”C, with either 1: 10 dilu- 
tion of rabbit anti-o,HS glycoprotein (Behringwerke) 
in RPMI/FCS or 1: 10 dilution of non-immune rabbit 
serum in RPMI/FCS as control. Cells were further 
washed and incubated, 60 min at 22’C, with 1: 10 
dilution of sheep anti-rabbit-FITC serum (Wellcome) 
in RPMI/FCS. Following final washing the cells were 
viewed under UV light. 
2. Materials and methods 
CQHS glycoprotein was isolated from serum [4] 
and stored at -20°C (1.6 mg/ml in phosphate-buffered 
saline, PBS). 
Peripheral blood lymphocytes (PBL) were separated 
by density-gradient centrifugation and transformed 
[7] with EBV-containing culture supernatants derived 
from the B95-8 cell line. The EBV-transformed cell 
line was free from bothMycopZusma and bacterial 
infection. Both transformed and normal autologous 
1251-I.abelled cr2HS glycoprotein [S] was used to 
further analyse the binding to transformed lympho- 
cytes. Aliquots (50 ~1) of cell suspension in RPM1 were 
added to 50 /.d 12sI-02HS glycoprotein (1 c(g containing 
lo6 cpm/pg in PBS) in siliconised glass tubes for incu- 
bation at 4°C. Following incubation, ice-cold RPM1 
(300 ~1) was dispensed into each tube and the con- 
tents layered onto a cold Ficoll-hypaque density gra- 
dient, specific gravity 1.040, and centrifuged at 
5000 rev./mm for 30 min. The supernatant was aspi- 
rated and the pelleted cells resuspended in Ca*+,Mg*+- 
free Hanks balanced salt solution (HBSS) containing 
0.1% trypsin, 0.2% EDTA (100 4). The cell suspen- 
sion was transferred to tubes for counting the cell 
bound ‘*‘I-a2HS glycoprotein. Blanks were also per- 
formed in the absence of cells to measure non-specific 
binding. Binding was expressed as cpm. 
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Fig.1. Binding of o,HS glycoprotein to EBV-transformed 
lymphocytes by indirect immunofluorescence. Cells were 
incubated with an equal volume of o,HS glycoprotein solu- 
tion, then with either rabbit anti-o,HS glycoprotein (a), or 
non-immune rabbit serum as control (b), and finally with 
fluorescein-labelled sheep antibody to rabbit serum. 
3. Results and discussion 
There was bright fluorescence in the transformed 
cells incubated with rabbit anti-ozHS glycoprotein 
serum with virtually no fluorescence in either the 
control (non-immune rabbit serum) (fig.1) or in nor- 
mal autologous lymphocytes, whether stained imme- 
diately or following 1 or 8 days in culture (table 1). 
The fluorescence observed in the transformed compared 
to normal autologous lymphocytes is unlikely to be 
due simply to the B cell selectivity of the virus as nor- 
mal B cells cultured in this medium show increased 
proliferation compared to T cells (P. S. C., unpublished). 
Specificity of immunofluorescence was confirmed by 
the use of o,HS glycoprotein antiserum absorbed with 
CQHS glycoprotein. The absorbed antiserum failed to 
react with normal human serum by immunodiffusion 
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Table 1 
Binding of a,HS glycoprotein to EBV-transformed and 
normal non-transformed autologous lymphocytes by indirect 
immunofluorescence 
Cell type Fluorescence 
EBV-transformed lymphocytes + 
Normal lymphocytes (t = 0) - 
Normal lymphocytes (f = 1 day) _ 
Normal lymphocytes (t = 8 days) - 
Indirect immunofluorescence of viable EBV-transformed 
lymphocytes (10’) andviablenormalautologouslymphocytes 
(10’) stained immediately t = 0; and following 1 or 8 days 
culture in Hepes-buffered RPM1 supplemented with 15% FCS 
and 2 mM L-glutamine. PBL from the original donor served 
as the normal non-transformed autologous cell control 
and did not produce fluorescence with the transformed 
cells. 
With ‘251-cxzHS glycoprotein binding equilibrium 
was attained after 30 min and was dependent oncell 
concentration (fig.2a,b). The dose dependence of
o,HS glycoprotein is shown (fig.3). Scatchard plot 
analysis [9] (inset fig.3), revealed Kd = 5.0 X lo-’ M 
with 0.5 X lo6 sites/cell. The affinity is similar to that 
of (r2HS glycoprotein for calf thymus DNA, Kd = 
9.0 X lo-’ M (unpublished). 
We speculated that DNA might be implicated in 
binding of (w2HS glycoprotein to transformed cells. 
However, pre-treatment of the EBV-transformed cells 
with DNase (0.5 mg/ml in HBSS) 2000 Kunits units/ 
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Fig.2. Binding of ‘251-o,HS glycoprotein to EBV transformed lymphocytes. Dependence on incubation time at 4°C (10’ cells) 
after blank value correction (a), mean f SEM, n = 4; and cell concentration (expressed as cell no./50 ~1 aliquot) for 60 min incu- 
bation at 4°C (b), mean f SEM, n = 5. 
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oaHS glycoprotein acts as an opsonin during bac- 
terial phagocytosis by human neutrophils [1 ] and 
enhances latex phagocytosis by macrophages [2,3]. 
These findings of the binding of 02HS glycoprotein to
EBV-transformed lymphocytes necessitate investiga- 
tions as to whether oaHS glycoprotein can stimulate 
macrophage-mediated phagocytosis or enhance T cell- 
mediated cytolysis of these transformed cell lines. In 
addition, the binding of o,HS glycoprotein to other 
EBV-carrying and EBV-negative cell lines merits inves- 
tigation. 
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Fig.3. Concentration dependence of ‘z51-e,HS glycoprotein 
on binding after blank value correction. Cells (0.6 X 10’) 
incubated for 60 min at 4°C with varying amounts of ‘% 
o,HS glycoprotein containing 0.45 X lo6 cpm/Hg. The 
Scatchard plot (inset) revealed Kd = 5.0 X lo-’ M with 
0.5 X lo6 sites/cell. Each point is the mean of triplicate 
determinations. 
mg, did not significantly diminish fluorescence or 
binding of 12’I-02HS glycoprotein. Although we have 
demonstrated that 02HS glycoprotein, at physiological 
concentration (0.8 mg/ml), binds appreciably to EBV- 
transformed lymphocytes the nature of the receptor 
remains obscure. Preliminary experiments indicate both 
fluorescence and binding of ‘251~2HS glycoproteln 
can be partially blocked by pre-treatment of the trans- 
formed cells with RNase (2 mg/ml in HBBS) 80 Kunitz 
units/mg or pronase (2 mg/ml in HBBS), although 
direct confirmation awaits isolation of the 02HS glyco- 
protein receptor. Interestingly, B cells harbouring the 
EBV genome can synthesise novel RNAs which may 
be complexed with protein [ 10,l l] and have been 
located in the cytoplasm. Whether such complexes 
become associatedwith e outer membrane isunknown 
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